equitieswatch
Wednesday, February 8, 2023
About us
Advertise
  • Home
  • Stock Market
  • Finance
  • Cryptocurrency
  • Commodities
No Result
View All Result
Equitieswatch.com
No Result
View All Result

COVID therapies and vaccines propel rise in spending on medicines in 2021 (NYSE:PFE)

by equitieswatch
April 24, 2022
in Finance

Petmal/iStock via Getty Images

Demand for COVID-19 vaccines and therapies helped contribute to a 12% increase in spending on medicines in the U.S. in 2021, according to the IQVIA Institute for Human Data Science.

U.S. spending on medicines reached $407B last year, with COVID-19 vaccines and therapeutics adding $29B to that amount.

IQVIA’s (IQV) report, The Use of Medicines in the U.S. 2022, found that prescription drug use reached 194B daily doses in 2021, a new record. However, new prescriptions dispensed for acute and chronic medicines has yet to return to pre-pandemic levels.

The use of biosimilars — generic versions of expensive biologic-based drugs — increased significantly and offset increased use of branded medicines.

Specialty medicines now account for 55% of all spending driven by growth in autoimmune and oncology treatments. A decade ago, these medicines only accounted for 28% of spend.

In 2021, patient out-of-pocket costs rose $4B to $79B.

The report also found that health services utilization returned to pre-pandemic levels by the end of 2021. However, it has not yet made up for the backlog of mixed healthcare visits.

Telehealth visits, which accounted for less than 1% of all doctor visits prior to the pandemic and reached 15% in April 2020, accounted for ~4% in the second half of 2021.

IQVIA (IQV) predicted that use and spending on medicines in the U.S. will return to pre-pandemic growth by 2023, with a compund annual growth rate of 1%-4% through 2026.

The reported noted that more than 250 new drugs are expected to launch in the next five years adding more than $100B in new spending. Immunology, oncology, and neurology therapies will spearhead this growth.

Selected pharma/biotech companies: Pfizer (NYSE:PFE), Merck (NYSE:MRK), Eli Lilly (LLY), Johnson & Johnson (NYSE:JNJ), Bristol-Myers Squibb (BMY), Moderna (MRNA), AstraZeneca (AZN), Novartis (NVS), GlaxoSmithKline (GSK), Roche (OTCQX:RHHBY), Sanofi (SNY), BioNTech (BNTX), Amgen (AMGN), Gilead Sciences (NASDAQ:GILD), and Regeneron Pharmaceuticals (REGN).

According to data from Rx Savings Solutions, drugmakers increased the list prices of prescription medicines by an average of 6.6% during the first few weeks of 2022.

Source link

YOU MAY ALSO LIKE

The U.S. is hurtling toward a recession. Here’s the best-case scenario for how it could play out—and the worst

Bitcoin Breaches $20,000 for the First Time Since 2020

ShareTweetPin

Search

No Result
View All Result

Recent News

Oil slips further on demand, financial market worries By Reuters

Oil Sinks Further Amid China Concerns, Weakened Economic Prospects By Investing.com

October 25, 2022
Gold Up, Set for Second Weekly Gain as Dollar Falls from 20-Year High By Investing.com

Gold Pressured Near $1,650, Copper Muted on Economic Fears By Investing.com

October 25, 2022
Explainer-What would be the impact of Russian oil sanctions in Europe? By Reuters

Oil prices edge higher as U.S. dollar eases By Reuters

October 25, 2022
Equitieswatch.com

Equitieswatch.com is your Stock Market, Finance, Forex, Cryptocurrency, Business, NFT News Website. We provide you with the latest breaking news and videos straight from the Business industry.

  • Home
  • About us
  • Contact
  • Privacy Policy

© 2022 www.equitieswatch.com

No Result
View All Result
  • Home
  • Stock Market
  • Finance
  • Cryptocurrency
  • Commodities

© 2022 www.equitieswatch.com